SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Mankind Pharma - Quaterly Results

21 May 2025 Evaluate
A fair growth of 5.93% in the revenue at Rs. 21265.90 millions was reported in the March 2025 quarter as compared to Rs. 20074.70 millions during year-ago period.A slender decline of -13.95% was recorded to Rs. 3824.60  millions from Rs. 4444.40 millions in the corresponding previous quarter.OP of the company witnessed a marginal growth to 6962.40 millions from 6107.40 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 21265.90 20074.70 5.93 94978.00 86292.50 10.07 94978.00 86292.50 10.07
Other Income 2193.20 849.60 158.15 4932.10 2705.00 82.33 4932.10 2705.00 82.33
PBIDT 6962.40 6107.40 14.00 30557.60 25367.90 20.46 30557.60 25367.90 20.46
Interest 1622.50 42.90 3682.05 3717.60 163.30 2176.55 3717.60 163.30 2176.55
PBDT 5339.90 6064.50 -11.95 26840.00 25204.60 6.49 26840.00 25204.60 6.49
Depreciation 1052.40 866.20 21.50 3780.10 3352.60 12.75 3780.10 3352.60 12.75
PBT 4287.50 5198.30 -17.52 23059.90 21852.00 5.53 23059.90 21852.00 5.53
TAX 462.90 753.90 -38.60 4217.40 4125.70 2.22 4217.40 4125.70 2.22
Deferred Tax -467.80 -277.60 68.52 -481.90 12.40 -3986.29 -481.90 12.40 -3986.29
PAT 3824.60 4444.40 -13.95 18842.50 17726.30 6.30 18842.50 17726.30 6.30
Equity 412.60 400.60 3.00 412.60 400.60 3.00 412.60 400.60 3.00
PBIDTM(%) 32.74 30.42 7.61 32.17 29.40 9.44 32.17 29.40 9.44

Mankind Pharma Share Price

2123.20 18.50 (0.88%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×